File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Global antiplatelet sales trend: a focus on P2Y12 inhibitors from 2008 to 2018

TitleGlobal antiplatelet sales trend: a focus on P2Y12 inhibitors from 2008 to 2018
Authors
KeywordsP2Y12 inhibitors
Sales trends
Income level
Antiplatelets
Drug utilization
Issue Date2021
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ahj
Citation
American Heart Journal, 2021, v. 4, p. article no. 100020 How to Cite?
AbstractBackground: P2Y12 inhibitors are an important component of dual antiplatelet therapy. Yet, their accessibility and affordability across countries stratified by income levels have not been studied. Methods: Sales data were retrieved from the IQVIA Multinational Integrated Data Analysis System for the description of P2Y12 inhibitors global sales. Countries were stratified into 38 high-income countries and 27 middle-income countries. Results: Global sales of P2Y12 inhibitors increased from 0.80 SU per year per person in 2008 to 1.79 in 2018. Growth in sales of P2Y12 inhibitors was greater in middle-income countries compared to high-income countries. Clopidogrel had the highest sales volume in both high-income and middle-income countries from 2008 to 2018, while ticagrelor sales volume increased mainly in high-income countries. Conclusions: Despite current guideline recommendations favoring ticagrelor and prasugrel for the prevention of atherothrombotic complications in patients with an acute coronary syndrome, clopidogrel retained the highest sales volume among the P2Y12 inhibitors from 2008 to 2018.
DescriptionHybrid open access
Persistent Identifierhttp://hdl.handle.net/10722/301166
ISSN
2023 Impact Factor: 3.7
2023 SCImago Journal Rankings: 2.109

 

DC FieldValueLanguage
dc.contributor.authorYE, X-
dc.contributor.authorSHAMI, JJP-
dc.contributor.authorYan, VKC-
dc.contributor.authorKANG, W-
dc.contributor.authorBLAIS, JE-
dc.contributor.authorZHAO, J-
dc.contributor.authorLau, WCY-
dc.contributor.authorWei, LI-
dc.contributor.authorWong, ICK-
dc.contributor.authorChan, EW-
dc.date.accessioned2021-07-27T08:07:05Z-
dc.date.available2021-07-27T08:07:05Z-
dc.date.issued2021-
dc.identifier.citationAmerican Heart Journal, 2021, v. 4, p. article no. 100020-
dc.identifier.issn0002-8703-
dc.identifier.urihttp://hdl.handle.net/10722/301166-
dc.descriptionHybrid open access-
dc.description.abstractBackground: P2Y12 inhibitors are an important component of dual antiplatelet therapy. Yet, their accessibility and affordability across countries stratified by income levels have not been studied. Methods: Sales data were retrieved from the IQVIA Multinational Integrated Data Analysis System for the description of P2Y12 inhibitors global sales. Countries were stratified into 38 high-income countries and 27 middle-income countries. Results: Global sales of P2Y12 inhibitors increased from 0.80 SU per year per person in 2008 to 1.79 in 2018. Growth in sales of P2Y12 inhibitors was greater in middle-income countries compared to high-income countries. Clopidogrel had the highest sales volume in both high-income and middle-income countries from 2008 to 2018, while ticagrelor sales volume increased mainly in high-income countries. Conclusions: Despite current guideline recommendations favoring ticagrelor and prasugrel for the prevention of atherothrombotic complications in patients with an acute coronary syndrome, clopidogrel retained the highest sales volume among the P2Y12 inhibitors from 2008 to 2018.-
dc.languageeng-
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ahj-
dc.relation.ispartofAmerican Heart Journal-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectP2Y12 inhibitors-
dc.subjectSales trends-
dc.subjectIncome level-
dc.subjectAntiplatelets-
dc.subjectDrug utilization-
dc.titleGlobal antiplatelet sales trend: a focus on P2Y12 inhibitors from 2008 to 2018-
dc.typeArticle-
dc.identifier.emailYan, VKC: kcyan96@hku.hk-
dc.identifier.emailLau, WCY: wallisy@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.authorityChan, EW=rp01587-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.ahjo.2021.100020-
dc.identifier.hkuros323770-
dc.identifier.volume4-
dc.identifier.spagearticle no. 100020-
dc.identifier.epagearticle no. 100020-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats